Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials

Published:2017-11-22 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Zhang Fang,Tang Lizhi,Zhang Yuwei,Lü Qingguo,Tong Nanwei

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-16018-9.pdf

Reference46 articles.

1. Chan, J. C., Malik, V. & Jia, W. et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 301(20), 2129–40 (2009).

2. Ramachandran, A., Ma, R. C. & Snehalatha, C. Diabetes in Asia. Lancet. 375(9712), 408–18 (2010).

3. He, L., Tuomilehto, J. & Qiao, Q. et al. Impact of classical risk factors of type 2 diabetes among Asian: Indian, Chinese and Japanese populations. Diabetes Metab. 41(5), 401–9 (2015).

4. Wang, C., Li, J. & Xue, H. et al. Type 2 diabetes mellitus incidence in Chinese: contributions of overweight and obesity. Diabetes Res Clin Pract. 107(3), 424–32 (2015).

5. Kim, Y. G., Hahn, S. & Oh, T. J. et al. Differences in the HbA1c-lowering efficacy of glucagon-likepeptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 6(10), 900–9 (2014).

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials;Journal of Clinical Lipidology;2024-07

2. Comparing Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Agonist Versus Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Chinese Patients with Type 2 Diabetes Mellitus: A Preliminary Study;International Journal of Pharmacology;2024-05-01

3. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study;Biomedicines;2023-03-13

4. Obesity among Asian American people in the United States: A review;Obesity;2023-01-25

5. Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus;International Journal of Clinical Practice;2022-10-10